Search All News
Lisa Kachnic, MD, the new chair of radiation oncology at Columbia University Irving Medical Center, has helped pioneer techniques that deliver radiation therapy to cancer patients with more precision.
A new drug that penetrates the protective barrier around pancreatic cancers and accumulates in malignant cells may improve current chemotherapy, a study in mice suggests.
Researchers in Columbia's medical and engineering schools have edited a strain of non-pathogenic bacteria to colonize solid tumors in mice and safely deliver potent immunotherapies.
Barring ovarian cancer surgery at low-volume hospitals could limit access to care for many rural and underserved patients, a new study has found.
- October 29, 2015
Columbia researchers Andrea Califano and Jean Gautier have received prestigious NCI awards that support and encourage leaders in cancer research.
- October 28, 2015
Columbia has one of six new sites launched by the NIH's Breast Cancer and Environment Research Program for prevention and research across the lifespan.
- October 21, 2015
According to a recent study, a microsurgical approach is found to be a safe and effective technique to prevent breast cancer-related lymphedema.
- October 12, 2015
Andrea Califano and his investigative team discover a molecular signaling mechanism underlying a specific type of highly aggressive breast cancer.
- October 5, 2015
KEYTRUDA is an immunotherapy that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, helping the immune system to help detect and fight cancer cells.
- September 23, 2015
The Columbia Combined Cancer Panel has been granted full approval by the New York State Department of Health.
- September 18, 2015
Dr. Naiyer Rizvi, director of thoracic oncology at CUMC, offers updates on immune checkpoint inhibitors in certain forms of lung cancers.
- May 26, 2015
Columbia scientists have created new decoy drugs that can intercept the deceptive growth signals that cancer cells send out.
- April 14, 2015
A study of the genomes of patients with a particularly aggressive form of non-Hodgkin’s lymphoma shows that many cases are driven by alterations in the JAK/STAT3 cell signaling pathway.